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This p aper describes the study population an d  the study design o f  the phase III fie ld  
trial o f  the SPf66 vaccine in Brazil. Assessment o f  validity an d  precision principles 
necessary fo r  the appropriate evaluation o f  the protective effect o f  the vaccine are  
discussed, as well as the results o f  the preliminary analyses o f  the gathered data. The 
analytical approach fo r  the estimation o f  the protective effect o f  the vaccine is presented. 
This p ap er  provides the conceptual fram ew ork fo r  fu ture publications.
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The main objective of a vaccine phase III 
trial is to estimate the direct protective effect of 
the vaccine in the individual (vaccine efficacy) 
or, in other words, the alteration of the 
vaccinated individual’s susceptibility to 
infection4 22 2<s. In order to obtain a valid and 
precise estimation of the efficacy of a vaccine 
that allows for a biological meaningful 
interpretation, several conditions must be 
satisfied in a field trial.
Wi th t he  p u r p o s e  o f  provi di ng the 
conceptual framework of the phase III trial of 
SPf66 vaccine against the asexual blood-stages 
of P lasm odium  fa lc ip a ru m  in Brazil, we 
w orked based upon the sequ en ce of 
pathogenic processes that would lead to the 
endpoint(s) of interest the vaccine is suppose 
to prevent or modify as illustrated by 
Struchiner et al.21. Such framework divides the 
process in three sequences, each one with 
important issues of validity and precision
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principles: 1) selection of a susceptible study 
population, determination of an adequate 
sample size, definition and measurement of 
relevant factors (covariates), and the random 
vaccine allocation; 2) determination of the 
amount of exposure to infection the study 
population is subjected to; and 3) the 
definition of a response model.
Study a rea  a n d  population . The field trial 
was carried out in the rural settlements o f  the 
municipality of Costa Marques, Rondonia in 
the Amazon basin of Brazil. The region is 
characterized by a hot humid, equatorial 
climate, with seasonal distribution of rains (dry 
season from May to September and a rainy 
season from October to April). The vegetation 
is composed of dense tropical forest9.
In the past 15 years, Costa Marques showed 
a significant increase of its population. In 1980, 
the municipality had a population of 2,998 
inhabitants distributed in the urban (village of 
Costa Marques and Forte Principe da Beira), 
and rural areas (communities along the 
Guapore river) each with 1,227 and 1,771 
inhabitants, respectively9. Immigration of 
hundreds of people from different regions of 
the country took place after the opening of a 
road to the municipality (BR 429) in 1985, and 
the promotion of colonization by the Brazilian 
Government. The migrants settled mainly in 
the village of Costa Marques and along the 
new opened road. Using the information 
gathered by the National Health Foundation 
(FNS) on the number of inhabitants per house 
sprayed (coverage greater than 95%) in 1991, 
we estimated the urban population in 
approximately 14,445 inhabitants. Along the
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river, the approximate population size was 
2,625, and along the road, the population was, 
5,975 for a total of 23,045 inhabitants (FNS: 
unpublished data).
The number of cases reported by the FNS, 
showed a dramatic and progressive increase 
during the 80’s, apparently related to the 
migratory influx. In 1983, 3,125 cases were 
reported in contrast to 16,029 cases in 1987. 
The dramatic increase in the number of cases 
and the progressive occupation of the forest, 
stimulated the establishment of specialized 
centers along the road where free diagnosis 
and treatment is offered to the population. 
Health agents were trained to refer to the main 
health center in the village all possible severe 
cases. Biannual spraying of all houses with 
in s e c t ic id e s  o f  res id u a l a c tio n  and the 
treatment of presumptive cases detected by 
active search in the field were maintained. A 
reduction in the number of cases was then 
observed, probably due to the strengthening of 
the active and passive case detection 
procedures, as this control measure has an 
impact on transmission (7,532 cases were 
reported in 1990). Although malaria is 
considered the main health problem in the 
municipality, mortality is low probably due to 
the easy access by the population to diagnosis 
and specific treatment24.
Malaria cases have a seasonal distribution, 
being higher during the beginning and the end 
of the rainy season. During the early colonization 
stage and before the strenghthening of control 
measures, the prevalence of malaria varied 
between 8 to 26%, according to the area. In the 
communities along the road the prevalence 
ranged between 14 to 26%, and in the village 
between 8 to 9%, being the ratio of P. 
falciparum  and P. vivax infections 2:1. Spleen 
rates in children 2 to 10 years old ranged from 
17% to 67% (depending on the year season), 
both in residents of the urban and rural area, a 
mesoendemic transmission level15. Cases were 
observed in all age groups and parasitemia 
was usually accompanied by the classical 
symptoms being subclinical infections, an 
exceptional finding17. The prevalence in infants 
was of 9% and the intensity of clinical 
manifestations had no apparent relationship 
with age. Malaria infections during pregnancy 
did not relate with parity. In addition, 
com plications associated with parasitemia 
during gestation were rare, as well as congenital
malaria, probably due to the frequent 
therapeutic use of antimalarials. IgG antibodies 
against asexual blood forms of P. falciparum  
were detected in 42% of the parturients at very 
low titers and showed a rapid decay23. In the 
last past years, P. vivax infections predominate 
and a reduction on prevalence was observed, 
achieving 10% in a preliminary survey for the 
vaccine trial done in residents along the road 
in 1990.
T h e FNS th e ra p e u tic a l sch em es fo r 
treatment of malaria caused by P. falciparum  
have changed frequently during the past few 
years, due to the occurrence of multidrug 
resistance, as suggested by in vivo studies16. 
Chloroquine is used exclusively for the 
tre a tm e n t o f P. v iv a x  in fe c t io n s , s in ce  
sensitivity of P. falciparum  to it was 18.2%. 
The sensitivity to sulfadoxine-pyrimethamine 
was 53-4%, to quinine of 81.8% and to quinine 
plus tetracycline of 93%. The present treatment 
scheme is based on the combination of 
quinine plus tetracycline in patients older than 
seven years of age and non-pregnant women. 
During pregnancy, the first line treatment is 
quinine in a 10 days schedule. Mefloquine is 
available and prescribed in case of resistance 
to the conventional scheme.
Anopheles darlingi is the main local vector 
of P. falciparum  and P. vivax malaria, and 
corresponds to 91% of the thirteen species 
identified in Costa Marques1011 n. Studies on the 
biting behavior showed that A. darlingi were 
active throughout the night with peak biting 
activities in the early morning and evening. 
Together with A. deaneorum , A. darlingi is the 
most anthropophilic and endophilic species of 
anophelines in the region13. Although they can 
be captured throughout the year, the population 
distribution of anophelines is closely related to 
the water levels of the Guapore River and its 
tributaries, as well as with the beginning and 
ending of the rainy season. Upon closer 
examination of the data gathered in these 
surveys, the average biting rate per man per 
night in the near housing areas ranged from 53 
to 301, depending on the year season, being 
lowest during the last trimester of the year, and 
highest on the second. Preliminary data 
suggested that the proportion of P. falciparum  
infected anophelines captured was 0,7%, as 
determined by ELISA. However, less than 50% 
of these anophelines had sporozoites in their
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salivary glands (TA Klein: personal communication, 
1989).
The population of interest for the field trial 
was that settled along the road, as it is 
composed mainly of migrants. After arriving to 
the area, the main activities of the immigrants 
were the building of temporary shelters, 
clearing the forest and, growing subsistence 
crops. They are very unstable, since their 
permanence depends mainly on economic 
success and health conditions. Once settled, 
the main occupations are agriculture and 
lumbering15.
The clinical, serological and entomological 
data, as well as the population dynamics, 
characterize Costa Marques as an “agricultural 
frontier”25 of medium endemicity, with periods 
of higher and lower transmission, occupied 
recently by non-immune individuals.
SP/66 vaccine. The synthetic vaccine SPf66 
consisted of a sequence of three fragments 
derived from merozoite proteins linked by a 
s e q u e n c e  o f th e  te tra p e p tid e  o f the 
circumsporozoite protein of P. falciparum. 
One milliliter of the product contained 4mg of 
the synthetic peptide solubilized in saline 
solution absorbed onto 2mg of aluminum 
hydroxide1. It was produced in the Instituto de 
Inmunologia, Universidad Nacional de Colombia 
by the research group of Dr. M.E. Patarroyo. 
The vaccine, as well as the placebo (tetanus 
toxoid for 1st and aluminum hydroxide for 2nc* 
and 3rc* doses), were bottled in clear glass 
recipients containing 10 doses each and coded 
with the letters S and L in Colombia. The 
vaccination schedule was defined as the 
subcutaneous application of 0.5ml on days 0, 
30 and 18018.
The possible direct effects of SPf66 malaria 
vaccine are the m odification of clinical 
manifestations, including duration, since its 
main mechanism of action would be the 
induction of the production of specific 
antibodies against antigens of the asexual 
forms of P. falciparum , capable of limiting 
their multiplication19. The vaccine mechanism 
of action would mimic the acquisition of 
partial immunity observed naturally in highly 
endemic areas.
Incidence of clinical cases could be reduced 
by indirect means. The protective agent could
in te rfe re  w ith  the h e p a tic  sch iz o g o n y , 
preventing the development of parasitemia 
simulating the effect of a vaccine that prevents 
infection. If the protective effect of the vaccine 
is manifested by the presence of subclinical 
parasitemias, a reduction in the reported 
number of clinical cases will be noticed 
and/or, if the duration of parasitemia is 
diminished, there could be an effect on the 
production of the sexual forms altering 
transmission7 20 26.
Study design. The objective of this trial was 
to evaluate the efficacy, immunogenicity and 
safety of the SPf66 vaccine in non-immune 
residents of a Brazilian endemic region. The 
main specific objectives were: first, to estimate 
the overall protective direct effect of the 
vaccine for all episodes, as well as crude and 
stratum specific estimates for the first and 
second episodes separately for P. falciparum  
and P. vivax infections. A futher objective was 
to detect possible differences in asexual blood- 
stage parasite densities. Second, to assess the 
immunogenicity of the vaccine and its relation 
with malaria infections, as well as its possible 
relation with protection, and third, to describe 
and determine the frequency of immediate or 
delayed side-effects associated with the 
application of SPf66 vaccine.
The study consisted of a randomized, 
double-blinded, placebo-controlled, efficacy 
trial. All volunteers, male or female, aging 7 to 
60, resident in the rural settlements along km 
52 to 112 of the road BR 429 were randomly 
assigned to a number between one to 800. 
Individuals suffering of acute or severe 
diseases, with history of allergies and pregnant 
women were excluded. All participants with 
an odd number received the preparation 
labeled L and those with an even number the 
preparation labeled S, shipped “ready for use”, 
by the Colombian laboratory.
The required sample size was calculated 
according WHO’s guidelines for phase III field 
trials26. Considering a prevalence of 10% and a 
vaccine efficacy of 80% (as established in the 
first field trial1), the sample size to detect such 
a difference at a 5% level of significance with 
80% power was of 134 individuals in each 
group. Assuming a 30% loss to follow-up, the 
sample size increased to 179 subjects. Finally,
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adding a design factor of 2, a total of 358 
subjects in each treatment group seemed 
appropriate. We included 400 individuals in 
each group.
Study participants were registered with an 
individual identification number. The following 
information was recorded for each one: name, 
sex, age, site of residence, birth place, place of 
last residency, date of arrival to the study area, 
previous history of malaria episodes (number, 
usual symptoms and complications, date of last 
infection), and clinical history of allergies or 
other diseases.
Vaccine and placebo preparations were 
applied in three doses: the l s  ^ on day 0, the 
2nd on day 30 and the 3rd on day 180. The 
recommended dose of 0.5ml was applied 
subcutaneously in the deltoid region.. To 
facilitate the detection of local reactions, the 
first and third doses were applied on the right 
arm and the second, on the left.
Trial end-points: determination and  
measurement: Considering the objectives of 
the trial, several end-points were determined 
and measured: 1) incidence of malaria cases 
by species, 2) density of asexual blood-stage 
parasitemias, 3) determination of specific IgG 
antibodies against blood-stage antigens and 
vaccine peptides and, 4) frequency and 
description of side effects.
In order to determine the incidence of 
infection, two methods of evaluation were 
used: programmed periodic visits and passive 
and/or active search done by the FNS health 
agents. Periodical active searches were 
programmed on every vaccination (days 0, 30 
and 180), and at regular intervals: every two 
months in the first year of follow-up and every 
three months in the second (Table 1). Blood 
samples were obtained for parasitological 
examination in the field. The administration of 
an e ffe c t iv e  sc h iz o n tic id a l drug to all 
participants before the beginning of the trial 
was not done. Shortly after the application of 
either dose of the vaccine or placebo, all 
participants with asexual parasitemia were 
adequately treated. The microscopists in 
charge of the diagnostic and treatment stations, 
as well as the field agents, were responsible 
for the notification of all cases of infection 
identified in the study subjects during the 
whole study period by passive or active 
search, specially during the intervals between 
the programmed active searches. The subjects’
Table 1 - Activity chart.
Activity Evaluation
Day vaccination spleen sero-
parasitology
hct leucogram
0 1st dose X X X X
30 2nd dose X X X X
45 X X
90 X X
180 3rd dose X X X





540 1st year X X X
630 X X
720 X X X
3rd dose: August, 1991. End o f follow-up: February, 1993-
name, register number, date and parasitological 
result were adequately recorded in specific 
notebooks. A written laboratory report was 
given to the participant. Treatm ent was 
supplied in case of the presence of asexual 
parasitemia Health agents were instructed to 
preserve all thick blood films for further blind 
re-examination at the reference laboratory.
Incid en ce of m alaria in fectio n  was 
determined by the confirmation of the 
information obtained from each study subject 
by one of the following means: written 
parasitological reports given to the study 
subject, malaria infection records at the FNS 
stations, confirmation of asexual parasitemia 
by the revision of thick blood films in the 
reference laboratory and parasitological results 
obtained in the programmed active searches.
Malaria was diagnosed by the microscopic 
examination of thick blood films stained as 
recommended by the Pan American Health 
Organization14. All samples were examined by 
the FNS microscopist in the field. Negative 
results were determined after the observation 
of 200 microscopic fields. All samples (positive 
and negative) were preserved and sent to the 
Malaria Laboratory of the Núcleo de Medicina 
Tropical e Nutrição of the University of Brasilia, 
where a blind re-examination was carried out 
for reliability of results. Asexual blood-stage 
densities were calculated by counting asexual 
forms per 500 white blood cells and expressed 
as number of parasites per mm3. Evaluation of 
spleen size was performed in the prone 
position on every programmed vaccination, 
and on days 540 and 720.
Surveillance for mortality among study 
subjects was maintained. Information was
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obtained from members of the community, 
hospital registers and/or the FNS records.
During the programmed active searches, 
capillary blood samples were collected from 
the study subjects by finger puncture into three 
hep arin ized  m icrocap illary  tubes. After 
centrifugation and hematocrit determination, 
plasma samples were adequately packed, 
stored and taken to the Laboratory of Malaria 
of the University of Brasilia. IgG antibodies 
against asexual forms of P. falciparum  were 
d e t e r m i n e d  u s i n g  t h e  i n d i r e c t  
immunofluorescence method, as well as 
antibodies against the vaccine peptides 
(ELISA) for evaluation of immunogenicity.
A surveillance system for detecting any 
adverse reaction was set up during every 
programmed vaccination. All participants were 
closely monitored during the first 30 minutes 
by the medical investigator in charge of the 
applications. Em ergency equipm ent and 
therapeutic procedures were readily available. 
Inquiry for possible symptoms and identification 
of local reactions were performed two hours 
after each application, and four weeks after the 
1st dose and two weeks after the 2nc* and 3 
doses. Participants were advised to search for 
medical care in case of possible severe signs 
and symptoms secondary to vaccination. The 
frequency and intensity, as well as the 
description of any adverse effect, was 
systematically recorded.
Assessment o f  validity a n d  precision  
principles. A preliminary step in the analyses, 
is the description and critical evaluation of the 
data gathered during the study. During this 
phase, the assessment of validity and precision 
principles is necessary. Once determined, it is 
possible to define relevant epidemiologic 
categories, select parameters, define statistical 
models and establish the methods most 
appropriate for the estimation of vaccine 
efficacy and/or other endpoints of interest21.
The first happening that takes place in the 
process, is the selection of a susceptible study 
population. This is a straight forward condition 
for the evaluation of vaccine efficacy. The 
random allocation of the vaccine and placebo, 
as well as the “double-blindness”, were used 
w ith the in tention  of hom ogeneously  
distributing known and unknown sources of 
heterogeneity among “treatment” groups. 
Known factors (covariates), which can help 
discriminate possible heterogeneities of
exposure and/or susceptibility to infection 
among the study population, were identified 
and quantified during the study.
For determining the susceptibility to 
infection of the study population, information 
related with the number of previous malaria 
episodes, spleen size and presence of IgG 
antibodies against the asexual forms of P. 
f a l c i p a r u m  w as o b ta in e d  p rio r to  the 
beginning of the study. The presence of one or 
all of these variables, indirectly indicate that 
the participant was exposed, was capable to 
react inmunologically and was susceptible to 
infection. However, their absence does not 
necessarily imply resistance to infection 
(eventhough it is possible), since most of the 
individuals were migrants with different time 
since arrival to the endemic area.
Although we may assume an equal exposure 
to infection in both groups because of 
randomization, we can expect differences in 
the amount of exposure (heterogeneity) within 
each group. Transmission is also affected by 
seasonality, other concomitant control measures 
and by the vaccine itself, depending on the 
proportion of the population vaccinated (herd 
immunity). Baseline transmission levels prior 
to the intervention and during the study, can 
be approxim ated using inform ation that 
indirectly denotes differences in exposure to 
infection. We considered age, sex, time since 
arrival to the endemic area, reported number 
of previous malaria episodes, spleen size, and 
antibodies titers at the beginning of follow-up. 
Antibody determination and quantification, is a 
reasonable indirect indicator not only for 
susceptibility, but also for exposure to infection. 
Differences in exposure to infection are also 
related to the number of malaria episodes, as 
well as age and sex. Splenomegaly has been 
considered an indicator for malaria endemicity 
and therefore an indicator for exposure to 
infection, however, its value as an indicator for 
exposure is questionable in areas where rapid 
diagnosis and specific treatment are available 
to the population, as part of the control 
programs. The periodic measurement of the 
considered factors allows to track changes in 
e x p o su re  to in fe c t io n , as w ell as in 
susceptibility, which is altered by the vaccine.
Since the complete vaccination schedule of 
SPf66 vaccine consists in the application of 
three doses with a time interval of six months 
between the 1st and 3rc  ^ dose, several other
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aspects must be taken into account: 1) the 
modification of the initial cohort characteristics 
up to the m om ent of com pletion of the 
vaccination schedule given the presence of 
time-dependent covariates, such as, the number 
of malaria episodes and humural immune 
response, and 2) losses to follow-up, which 
would constitute an important limitation that 
affects mainly the precision of the estimate of 
vaccine efficacy, making necessary the 
determination of its magnitude and its causes. 
Both conditions may lead to the loss of the 
desired effect of randomization (comparability 
of the treatment groups) with time.
Therefore, the preliminary analyses of data 
includes the description of the the study 
p o p u l a t i o n  w ith  r e s p e c t  to  th e  
susceptibility/exposure factors previously 
discussed, assesment of randomization and 
definition of losses to follow-up.
Preliminary analyses of the data. The 
present study started in January 1991 and 
follow-up ended in February 1993- A total of 
800 volunteers of both sexes aging 7 to 60 
years, were randomly allocated to one of the 
treatment groups (400 participants on each 
group). Most of them were migrants (99-6%), 
natural of non-endemic areas of the country 
and residents in seven different localities of the 
rural area of Costa Marques.
Eventhough both treatment groups can be 
considered comparable at enrollment (Table 
2), the data suggests that the population is 
heterogeneous within each group, not only 
with respect to age and sex, but also related to 
the previous contact with malaria infection. A 
simple correlation analysis revealed that the 
number of referred previous malaria episodes 
as well as the antibody titers, are positively 
correlated with age (r = 0.16 and r = 0.19, p < 
0.001) and time since arrival to the endemic 
region (r = 0.37 and r = 0.22, p < 0.001). This 
suggests differences in exposure to infection 
among the participants. With respect to sex, 
males had in average more malaria episodes 
than females (4.6 and 3-1, respectively; p = 
0.002). However, no differences in time since 
arrival and antibody titers were detected 
between sexes. The prevalence of malaria 
infection at the beginning of the trial was low 
(5.6%). P. vivax (4%) predominated over P. 
falciparum (2%) infections. The proportion of 
participants infected in both groups with either







< 11 57 14 75 19 O.32
11 - 20 131 33 127 32
21 - 50 185 46 168 42
> 5 0 27 7 30 7
Sex
Male 247 62 245 61 0.88
Female 153 38 155 39
Time since arrival (years)
< 1 138 40 162 41 0.95
1 - 2 61 15 62 15
2 - 3 66 16 60 15
> 3 114 29 114 29
Previous malaria episodes
None 38 10 51 13 0.25
1 - 3 100 25 87 22
several 262 65 262 65
IFA antibodies
positive 115 29 115 29 0.88
negative 277 71 279 71
Spleen
palpable 90 23 99 26 0.40
unpalpable 297 77 284 74
Prevalence o f infection
P. falciparum 9 2 9 2 O.63
P. vivax 16 4 11 3
negative 367 94 370 95
*p-values for y}  tests for differences between groups
species was comparable. Classic symptoms 
related to malaria infection were referred by 
more than 95% of the participants in both 
groups.
Prior to intervention, at least 89% of the 
participants had being exposed to infection 
(by either sp ecies) and, therefore, w ere 
susceptible to it. Only 29% had detectable 
antibodies against the assexual form of P. 
falciparum at very low titers (less than l 60). 
After the completion of the vaccination 
schedule, 93% had at least one episode of 
malaria and 57% were seropositive.
The number of participants lost to follow- 
up before completing the vaccination schedule 
was considerable (28.5%). Of the initial cohort 
(800), 714 participants received the 2nd dose 
and 572 the 3r<^ - The most probable effects of 
losses are reducing the precision of the 
statistical estimate of vaccine efficacy and the 
introduction of selection bias2. Assessment of 
ramdoness of losses to follow-up, in the sense 
of being independent of the relationships 
under study3, is essential for evaluating the 
possible presence of selection bias and for 
assessing the comparability of the treatment 
groups.
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Losses to follow-up could be related with 
the disease (malaria episodes between the 1st 
and 3 dose), and/or with secondary adverse 
effects of the vaccine/placebo applications 
during the 1st and 2nd doses. To assess these 
possible relationships, four variables were 
created based on information, gathered during 
that period of time: num ber of times the 
participant had asexual parasitemia independent 
of the plasmodia species, number of times the 
individual searched for diagnosis, presence or 
not of secondary adverse reactions during the 
1 st a n d / o r 2 nd a p p l ic a t io n  o f  th e  
vaccine/placebo, and time of survival until the 
application of the 3rc  ^ dose. Comparisons 
were made between survivors and lost to 
follow-up participants for each treatment 
group (Table 3).
Table 3 - Characteristics o f  lost to follow-up and survivors ivith 
respect to possible related variables.
Lost Survivors
Characteristic vaccine placebo P vaccine placebo P
n % n % n % n %
Parasitemia 0.8 0.6
never 54 48 61 53 135 47 145 51
once 33 29 33 29 76 27 75 26
twice 18 16 14 12 38 13 37 13
> Twice 8 7 7 6 38 13 28 10
Diagnoses search 0.3 0.9
never 35 31 49 42 85 30 85 30
1 - 2 53 47 41 36 108 38 110 39
3 - 5 16 14 16 14 73 25 69 24
> 5 9 8 9 8 21 7 21 7
Adverse reactions 0.3 <0..001
yes 23 20 17 15 105 37 33 12
no 90 80 98 85 182 63 252 88
Survival time (wks) 0.5 0.8
mean 12.5 11.5 26.5 26.5
Total 113 115 287 285 0.9
* p value for x 2 test for differences betw een groups and/or for 
comparison of means (t-student test).
The proportion of participants, as well as 
the average time of survival were comparable 
betw een both treatm ent groups in the 
participants lost to follow-up and survivors. No 
differences betw een the proportion of 
vaccinated and unvaccinated individuals were 
detected between lost to follow-up and 
survivors, in relation to the number of times 
they had detectable parasitemia or the number 
of times they searched for diagnosis (relation 
with disease). Eventhough the proportion of 
individuals with secondary adverse reactions
was significantly greater in the SPf66 group, 
the proportion of individuals lost to follow-up 
who had secondary reactions was considered 
equal for both treatment groups. Comparability 
between lost and survivors was also maintained 
with respect to all other variables. Losses seem 
to be independent of the disease and of 
secondary adverse reactions.
The main causes of losses were absence of 
the participants and the presence of any acute 
disease during the programmed vaccinations, 
and emigration of the study area. Deaths were 
not related to malaria or treatment (Table 4).
Table 4 - Causes o f  losses to follow-up before the completion o f the 
vaccination schedule.
Cause Vaccine Placebo Total
n % n % n %
Absence 59 52.2 58 50.4 117 51.3
Diseases 19 16.8 19 16.5 38 16.7
Emigration 16 14.1 20 17.4 36 15.8
Pregnancy 8 7.1 10 8.7 18 7.9
Withdrawal 8 7.1 5 4 3 n 5.7
Moved to urban area 2 1.8 2 1.7 4 1.7
Death 1 0.9 1 0.9 2 0.9
Total 113 100 115 100 228 100
The randomization effect was maintained 
after the completion of the vaccination schedule 
(Table 5), eventhough 111 (19,4%) of the 572 
participants who received the 3 dose were 
lost to follow-up in different periods of time. 
The main causes of losses were the emigration 
of the study area and transfer of residence to 
th e  u rb a n  a re a  (7 6 .6 %  an d  1 5 .3 % , 
respectively). Deaths not related to malaria 
were responsible for 2.7% and other intercurrent 
diseases for 1.8%. Three participants (2.7%) 
were excluded for using impregnated bednets 
and 1 (0.9%) was vaccinated with the wrong 
preparation. Fourty six percent of the 
participants lost to follow-up were vaccinated. 
The groups were considered homogeneous 
with respect to the causes of losses (%2; p = 
0 .6).
In this initial approach we concluded that 
the population selected for the trial was 
susceptible to infection. Apparently, the 
participants had different degrees of low 
acquired immunity, if any at all. The effect of 
randomization was maintained eventhough the 
considerable losses to follow-up, which we 
assume occured at random. Covariates which
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Table 5  - Cohort and lost to follow-up baseline characteristics after the completion o f  the vaccination schedule.
Vaccine Placebo
Characteristics lost survivors lost survivors
n % n % p* n % n % P'
Age
< 11 6 12 45 19 0.52 10 16 53 24 0.52
11 - 20 20 39 73 31 21 35 75 33
21 - 50 20 39 98 42 25 42 76 34
> 5 0 5 10 20 8 4 7 21 9
Sex
Male 28 55 149 63 0.27 36 60 135 60
Female 23 45 87 37 24 40 90 40
Time since arrival yrs
< 1 24 47 87 37 0.16 30 50 81 36 0.10
1 - 2 10 20 44 19 7 12 49 22
2 - 3 3 6 43 18 7 12 41 18
> 3 14 27 62 26 16 26 54 24
Previous malaria episodes
none7 14 17 1 0.18 9 ■15 26 12 0.77
1 - 3 15 29 57 24 14 23 53 23
several 29 57 162 69 37 62 146 65
IFA antibodies
positive 17 33 72 31 0.69 15 25 66 29 0.51
negative 34 67 164 69 45 75 159 71
Spleen
palpable 10 20 6 i 27 0.32 13 22 57 29 0.54
unpalpable 40 80 167 73 45 78 159 71
•p - value for %2 tests for differences betw een proportions.
indirectly discriminate between susceptibility 
and exposure of the participants to infection 
were determined. They will permit to create 
relevant epidemiologic categories, necessary in 
future analyses, to adjust estimates of vaccine 
efficacy or describe effect modifiers.
Analytical approach for estimating vaccine 
efficacy. The efficacy of a vaccine has been 
estim ated from 1 - RR, w here RR is some 
measure of relative risk. This could be attack 
rates, incidence rates, or secondary attack rates, 
among others. Such rates should represent the 
instantaneous probability of progress to the 
endpoint of interest (infection, clinical malaria 
or others) of the vaccinated and unvaccinated 
given an equal amount of exposure to 
infection21. However, ensuring that comparison 
populations are subjected to the same 
exposure of infection is difficult to achieve in 
the field. It is usual to encounter heterogeneity 
of exposure to infection in the study 
population, related to factors such as age, sex, 
occupation and socio-economic characteristics, 
among others. Besides, equal exposure to 
infection is not sufficient to determine a 
precise and meaningful estimate of the direct 
effect, since parameter estimates can vary with 
the amount of exposure. Therefore, the direct 
effect must be defined with respect to a given
amount of exposure to infection. In field 
studies of most infectious diseases the exposure 
to infection cannot be controlled by the 
observer. The term field efficacy applies to 
situations in the field where the intent is to 
measure direct effects and attempts are made 
to control for the amount of exposure. Direct 
effectiveness measures are those that include 
some interaction of indirect effects with the 
efficacy parameter, a situation that is common 
in field studies of most infectious diseases5 6 7 8.
Vaccine efficacy trials must also satisfy the 
exchangeability principle, which implies that 
the occurrencti»of the effect would be the same 
in the untreated as well as in the treated group 
if they had been treated, and vice versa6. On 
the other hand, this principle can only be 
achieved if the amount of exposure to 
infection is known and equal in both treatment 
groups. In studies which fulfill both conditions, 
it is possible to determine exposure rates 
(instantaneous probability of being bitten by 
infected mosquitos) for vaccinated and non­
vaccinated participants. These parameters are 
necessary for estimating unbiased rates of 
infection or disease given a certain amount 
and equal exposure to infection, for both 
groups, and correspond to the best estimates 
we can use for estimating the direct biological
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effect of the vaccine or vaccine efficacy. Lack 
of these information leads to the estimation of 
compound rates that describe the transition of 
the susceptible stage in vaccinated and 
unvaccinated to the endpoint of interest. 
M easu res o f v a c c in e  e ff ic a c y  b a sed  on 
compound rates tend to underestimate the 
efficacy of the intervention21.
The information gathered in this trial is 
reported as time to the event of interest 
(malaria episodes). This will allow us to 
calculate incidence density rates for both, 
vaccinated and unvaccinated groups. Baseline 
transmission, as well as susceptibility to 
infection of the study participants, will be 
determined indirectly by defining relevant 
epidemiologic categories that discriminate 
between exposure and susceptibility to 
infection and heterogeneities of both in the 
study population.
Based on the clinical characteristics of 
malaria infections in the study population, 
determined in previous studies, clinical malaria 
can be easily identified17. Therefore, a case of 
malaria will be define as the presence of P. 
falciparum or P. vivax blood-stage parasitemia. 
A new infection caused by either species will 
be defined as a positive parasitological 
examination in a participant observed to be 
free of parasitemia for at least 30 days since a 
previous positive slide. With this approach we 
intend to exclude from the analyses possible 
treatment failures, relapses or recrudescences. 
It will also permit to define the time at risk for 
each participant since both species of 
plasmodia considered are sensitive, up to a 
certain extent, to the antimalarials used for 
treatment for either species.
Estimates of the protective effect of the 
vaccine will be calculated for the interval 
between the application of the 2nc* and 3rc  ^
dose and after the completion of the vaccination 
schedule. We will consider an induction period 
of 30 days after the application of each dose. 
We intend to estimate the overall, as well as 
the crude and stratum specific estimates of the 
protective effect of SPf66 for the first and 
second episodes of P. falciparum and P. vivax 
infections separately.
One important issue will be taken, into 
account at this point. Since no radical 
treatment was administered to the participants 
before the application of the vaccine or 
placebo, we can expect that the immune
response to the vaccine may be modulated by 
intercurrent malaria infection. P. falciparum 
and/or P. vivax infections detected during the 
vaccine applications or induction periods, will 
be considered as covariates in the analyses.
Measures of the protective effect of the 
vaccine in this trial will be based on 
compound rates. Attempts will be made in the 
analyses to control for heterogeneities of 
exposure and susceptibility to infection in the 
study population. Therefore, the estimated 
protective effect that will be obtained will be 
that of field direct effectiveness. If subjected to 
correction using previous entom oligical 
information of the study area, estimates will be 
closer to the ideal concept of biological 
efficacy21.
RESUMO
O presente artigo descreve a população de estudo 
e o desenho do ensaio de campo de fase III da 
vacina sintética SPf66 no Brasil. São avaliados os 
princípios básicos de validade e precisão, essenciais 
para a estimação adequada da eficácia vacinai. Os 
resultados da análise exploratória de dados são 
discutidos assim como, a abordagem analítica para 
a estimação da eficácia vacinai. Este trabalho 
fornece o marco conceituai para futuras publicações.
Palavras-chaves: Vacina antimalárica. Ensaio 
de campo SPf66. Eficácia vacinai.
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